Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global X Robo Global Robotics & Automation ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Global X Robo Global Robotics & Automation ETF trades at $84.26. The key difference: Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ROBO | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $90.34 |
52-Week Low | $205.48 | $62.34 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
ROBO, a US-listed robotics and automation ETF, trades at $84.76, up 1.56% today amid a bullish technical setup with strong moving average support. Key financial ratios are not disclosed for the ETF, but thematic focus on AI-driven robotics gains traction. Recent news highlights sector momentum and strategic rebalancing toward physical AI infrastructure.
Outlook remains positive given bullish technical signals and sector tailwinds, though high RSI suggests near-term overbought risk. Investors gain diversified exposure to robotics growth, but face volatility from cyclical end markets and valuation pressures as AI themes mature.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
